Advinus Therapeutics, A TATA Enterprise, Meets Milestone in Drug Discovery Alliance

PUNE, India, November 5, 2014 /PRNewswire/ --

Advinus Therapeutics Ltd., the TATA promoted Pharmaceutical R&D Company, announced today that it has received the second milestone in its Research and Development Collaboration with Takeda Pharmaceutical Company Limited. The achievement of this milestone substantiates the successful path of the collaboration and confirms Advinus' proven strength in providing innovative solutions with speed and quality - essential ingredients for discovery of safe and effective medicines. Takeda's approval of the milestone underscores the trust and confidence the company has placed in Advinus' young and creative talent. A payment of $ 3 M has been made by Takeda to Advinus to mark the achievement.

In October 2012, Advinus and Takeda announced a multi-year multi-project collaboration in the area of drug discovery. In this collaboration, Advinus is responsible for carrying out all the research required to identify candidate molecules for clinical development in several therapeutic areas while Takeda is responsible for the development and commercialization of these candidates. In October 2013, Advinus met the milestone that was set to mark the end of the first year of the collaboration. The rapid progress of the research programs over the past year has resulted in the milestone to mark the completion of the second year of the collaboration.

"The rapid progression of the collaborative programs by Advinus' young and talented scientists has strengthened the Takeda Advinus partnership, and the approval of the milestone demonstrates the confidence that Takeda has in Advinus' ability to deliver novel and effective candidates for drug development in a rapid and cost effective manner," said Kasim Mookhtiar, CSO of Advinus.

About Advinus  

Advinus Therapeutics is a research based Pharma Company founded by global Pharma executives and promoted by the TATA group. The company is the first of its kind in India to offer end to end development services to the global Pharma, Agro and Biotech industry while creating long term value through internal and collaborative Drug Discovery. The primary focus of the company's discovery efforts are in Metabolic Diseases, Inflammatory Diseases and Pain/ Neurodegeneration. Advinus also has an interest in pursuing the discovery of novel therapies for neglected or developing world diseases. Advinus' drug development operations supports and supplements the client resources at increased levels of cost-efficiency by providing services in the areas of Process Development, Drug Metabolism and Pharmacokinetics, Clinical Pharmacology, Safety Assessment, Formulation Development and Analytical R&D. For company information, visit Advinus at http://www.advinus.com.

Contact:
Advinus
Joshua Daniel
Corporate Communications
+91-80-66553104
http://www.advinus.com

SOURCE Advinus Therapeutics Ltd

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED